Kennedy has also criticized GLP-1 weight-loss medications, including Ozempic, Wegovy, Mounjaro, and Zepbound
J Mater Chem A 7(36):2084020846 He Q, Ding L, Raheem A, Guo Q, Gong Y, Yu G (2021) Kinetics comparison and insight into structure-performance correlation for leached biochar gasification
Mounjaros dual action on both GLP-1 and GIP receptors enhances its ability to control blood sugar, often leading to better outcomes than older medications
Research news A University of Texas at El Paso study has found that people with type 2 diabetes or obesity who used glucagon-like peptide-1 receptor agonists had lower odds of alcohol, opioid, nicotine and cocaine use disorders, although researchers said clinical trials were needed before the drugs could be considered for addiction treatment A study led by researchers at The University of Texas at El Paso, USA, has found that the use of diabetes and weight loss medicines such as Ozempic was associated with a lower risk of alcohol, opioid, nicotine and cocaine use disorders